CELG Related Analyst Ratings
-
Baird Upgrades Celgene (CELG) to Outperform; Revlimid On The Rebound
-
BofA/Merrill Restarts Gilead at Buy; Amgen, Celgene at Neutral; Biogen at Underperform (GILD, AMGN, CELG, BIIB)
-
Celgene (CELG): Actionable Short Call Alert - Cowen
-
Cowen & Co Downgrades Celgene (CELG) to Underperform
-
Merriman Curhan Initiates Coverage on Celgene (CELG) with a Buy
-
Morgan Joseph Downgrades Celgene (CELG) to Hold On Valuation
-
Deutsche Bank Initiates Coverage on Celgene (CELG) with a Buy
-
Morgan Joseph Initiates Coverage on Celgene Pharmaceuticals (CELG) with a Buy
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
Goldman Sachs Downgrades Celgene Corporation (CELG) to Sell
-
Credit Suisse Downgrades Celgene (CELG) to Neutral
-
Bernstein Upgrades Celgene (CELG) to Outperform
-
Wachovia Maintains an Outperform Rating on Celgene (CELG); Long-Term Fundamentals Intact
-
Citi Maintains a 'Buy' on Celgene (CELG); Removed From Top Picks Live List
-
Oppenheimer Starts Celgen (CELG) at Outperform
-
RBC Capital Initiates Coverage on Celgene (CELG) with an Outperform
-
Citi Maintains a 'Buy' on Celgene Corp (CELG), Attractive Buying Opportunity
-
Ameriprise Financial Names Celgene (CELG) a Top Pick for 2009
-
Baird Downgrades Celgene (CELG) to Neutral
-
Color on Baird's Upgrade of Celgene (CELG)
-
Baird Upgrades Celgene (CELG) to Outperform
-
Cowen & Co Upgrades Celgene (CELG) to Outperform on Valuation
-
Citi Maintains 'Buy' on Celgene Corp (CELG), Sell-Off Overdone
-
ARGUS Maintains a Hold Rating on Celgene (CELG), Sees Volatile Trading
-
Citi Introduces Investment Research's TEN+ (Ten Exceptional Names Plus) List for 2008-09
-
Pacific Growth Upgrades Celgene (CELG) to Buy
-
Credit Suisse Downgrades Celgene (CELG) to Neutral
-
Pacific Growth Securities Initiates Coverage on Celgene (CELG) with a Neutral
-
Celgene (CELG): Stock looks bottomed - Citigroup
-
Celgene (CELG) Lower on Disappointing REVLIMID Data
-
Wachovia Starts Celgene (CELG) at Outperform
-
Banc of America Upgrades Celgene (CELG) to Buy
-
Who's The Next Biotech Target Following Celgene/Pharmion?
-
Citigroup Downgrades Pharmion Corp (PHRM) to Hold; Price Target $72
-
William Blair Starts Celgene (CELG) at Outperform
-
Cowen upgrades Celgen (CELG) to Outperform
-
Jim Cramer makes positive comments on PEP, K, BG, CELG, BDK and SLB
-
Jefferies & Co Initiates Coverage on Celgene (CELG) with a Buy
-
Lehman Brothers upgrades Celgene (CELG) to Overweight
-
Jim Cramer Makes Comments on WMT, TGT, CELG and SIRI
-
Bank of American Starts Celgene (CELG) at Neutral
-
Credit Suisse Starts Celgene (CELG) at Outperform
-
S&P Equity Research Downgrades Celgene Corp (CELG) to Buy
-
Jimm Cramer Makes Comments on GM, STI, FITB, CMA, CELG, ACI and JCI
-
Rodman & Renshaw Comments on the "Aftershock" of MEDI/AZN Deal
-
Sanford Bernstein Initiates Coverage on Celgene (CELG)
-
UBS Starts Celgene (CELG) at Buy
-
Jim Cramer Makes Positive Comments on MO, CELG and the Tech Sector
-
Merrill Lynch Raises Its Price Target on Celgene (CELG) to $73
-
Jim Cramer Makes Comments on WLP, CAH, AMGN, CELG, ZUMZ, NKE, MHGC & HLT
Back to CELG Stock Lookup
